Abbvie share price today

Name: Abbvie Share Price Today (NASDAQ: ABBV) - Abbvie Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

(ABBV)

Abbvie share price is $172.61 & ₹14,941.98 as on 22 Jan 2025, 2.30 'hrs' IST

$172.61

▲

1.05

(0.61%)

Market is closed - opens 8 PM, 22 Jan 2025

View live Abbvie share price in Dollar and Rupees. Guide to invest in Abbvie stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Abbvie, along with analyst recommendations, forecasts, and comprehensive financials.

Abbvie share price movements

Today's Low: $171.28
Today's High: $175.56
$172.61
0.77%
Downside
Day's Volatility :2.44%
Upside
1.68%
52 Weeks Low: $153.58
52 Weeks High: $207.32
$172.61
11.02%
Downside
52 Weeks Volatility :25.92%
Upside
16.74%

Abbvie Returns

Period	Abbvie Inc	Sector (Health Care)	S&P500
3 Months	-8.69%	-7.4%	2.4%
6 Months	-2.64%	-5.2%	8.9%
1 Year	2.42%	0.5%	23.9%
3 Years	29.81%	8.3%	36.4%

Abbvie Key Statistics

in dollars & INR

Previous Close	$171.56
Open	$172.16
Today's High	$175.555
Today's Low	$171.28
Market Capitalization	$303.2B
Today's Volume	$6.7M
52 Week High	$207.32
52 Week Low	$153.58
Revenue TTM	$55.5B
EBITDA	$25.6B
Earnings Per Share (EPS)	$2.87
PE Ratio	59.78
Dividend Yield	3.82%
Profit Margin	9.22%
Quarterly Earnings Growth YOY	-0.12%
Return On Equity TTM	56.41%

How to invest in Abbvie from India?

It is very easy for Indian residents to invest directly in Abbvie from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Abbvie stock in both Indian Rupees (INR) and US Dollars (USD). Search for Abbvie or ABBV on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Abbvie or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Abbvie shares which would translate to 0.005 fractional shares of Abbvie as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Abbvie, in just a few clicks!

Returns in Abbvie for Indian investors in Rupees

Investment Value

₹1,00,000

Abbvie investment value today

Current value as on today

₹1,07,203

Returns

₹7,203

(+7.2%)

Returns from Abbvie Stock

₹3,051 (+3.05%)

Dollar Returns

₹4,152 (+4.15%)

Indian investors sentiment towards Abbvie

-38.24%

Period: Oct 23, 2024 to Jan 21, 2025. Change in 30 Days versus previous period

Investment in Abbvie from India has reduced in the last 30 days as on Jan 22, 2025. -38.24% less purchase transactions for Abbvie in the last 30 days versus the previous period.

-18%

Period: Oct 23, 2024 to Jan 21, 2025. Change in 30 Days versus previous period

Search volume for Abbvie on INDmoney from India has reduced in the last 30 days as on Jan 22, 2025. -18% less investors are searching Abbvie in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Abbvie

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	15244	-1763.73	0.62%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	2664	0.00	2.56%

Global Institutional Holdings in Abbvie

Vanguard Group Inc
9.71%
BlackRock Inc
7.69%
State Street Corp
4.47%
JPMorgan Chase & Co
2.95%
Morgan Stanley - Brokerage Accounts
2.19%
Capital Research & Mgmt Co - Division 3
2.08%

Analyst Recommendation on Abbvie

Buy

65%Buy

34%Hold

0%Sell

Based on 35 Wall street analysts offering stock ratings for Abbvie(by analysts ranked 0 to 5 stars)

Based on 35 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Abbvie

What analysts predicted

Upside of 15.83%

Target:

$199.93

Current:

$172.61

Insights on Abbvie

Price Movement
In the last 7 days, ABBV stock has moved down by -2.3%
Decreasing Revenue
Abbvie Inc has experienced a stable revenue trend over the last two quarters, with revenue remaining constant at $14.46 billion in each quarter. There has been no average decrease in revenue, indicating a consistent performance.
Increasing Net Profit
Abbvie Inc has shown a positive trend in its net profit over the last four quarters. The company’s net profit has increased from $822 million to $1.56 billion, achieving an average growth of 17.4% each quarter.
ABBV vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 15.5% return, outperforming this stock by 11.4%
ABBV vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 198.6% return, outperforming this stock by 168.6%
Price to Sales
Abbvie Inc has a Price-to-Sales Ratio of 5.5, meaning investors are willing to pay $5.5 for every $1 of sales the company generates. In comparison, investors are willing to pay significantly more for Eli Lilly And Company, at $16.0 for every $1 of sales. This indicates that Abbvie Inc is valued lower by investors compared to Eli Lilly based on their sales performance.

Abbvie Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$32.8B	↑ 16.08%
Net Income	$5.7B	↑ 7.12%
Net Profit Margin	17.36%	↓ 1.46%

	FY19	Y/Y Change
Revenue	$33.3B	↑ 1.57%
Net Income	$7.9B	↑ 38.6%
Net Profit Margin	23.69%	↑ 6.33%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 37.69%
Net Income	$4.6B	↓ 41.44%
Net Profit Margin	10.08%	↓ 13.61%

	FY21	Y/Y Change
Revenue	$56.2B	↑ 22.69%
Net Income	$11.5B	↑ 150.04%
Net Profit Margin	20.54%	↑ 10.46%

	FY22	Y/Y Change
Revenue	$58.1B	↑ 3.3%
Net Income	$11.8B	↑ 2.55%
Net Profit Margin	20.39%	↓ 0.15%

	FY23	Y/Y Change
Revenue	$54.3B	↓ 6.44%
Net Income	$4.9B	↓ 58.91%
Net Profit Margin	8.95%	↓ 11.44%

	Q2 FY23	Q/Q Change
Revenue	$13.9B	↑ 13.42%
Net Income	$2.0B	↑ 746.86%
Net Profit Margin	14.6%	↑ 12.64%

	Q3 FY23	Q/Q Change
Revenue	$13.9B	↑ 0.45%
Net Income	$1.8B	↓ 12.15%
Net Profit Margin	12.77%	↓ 1.83%

	Q4 FY23	Q/Q Change
Revenue	$14.3B	↑ 2.69%
Net Income	$822.0M	↓ 53.77%
Net Profit Margin	5.75%	↓ 7.02%

	Q1 FY24	Q/Q Change
Revenue	$12.3B	↓ 13.92%
Net Income	$1.4B	↑ 66.55%
Net Profit Margin	11.12%	↑ 5.37%

	Q2 FY24	Q/Q Change
Revenue	$14.5B	↑ 17.48%
Net Income	$1.4B	↑ 0.07%
Net Profit Margin	9.47%	↓ 1.65%

	Q3 FY24	Q/Q Change
Revenue	$14.5B	↓ 0.01%
Net Income	$1.6B	↑ 13.94%
Net Profit Margin	10.8%	↑ 1.33%

	FY18	Y/Y Change
Profit	$25.0B	↑ 18.22%

	FY19	Y/Y Change
Profit	$25.8B	↑ 3.16%

	FY20	Y/Y Change
Profit	$30.4B	↑ 17.77%

	FY21	Y/Y Change
Profit	$38.8B	↑ 27.4%

	FY22	Y/Y Change
Profit	$40.6B	↑ 4.87%

	FY23	Y/Y Change
Profit	$33.9B	↓ 16.58%

	Q2 FY23	Q/Q Change
Profit	$9.6B	↑ 16.82%

	Q3 FY23	Q/Q Change
Profit	$7.4B	↓ 22.68%

	Q4 FY23	Q/Q Change
Profit	$11.9B	↑ 60.1%

	Q1 FY24	Q/Q Change
Profit	$8.2B	↓ 30.94%

	Q2 FY24	Q/Q Change
Profit	$12.3B	↑ 49.32%

	Q3 FY24	Q/Q Change
Profit	$10.2B	↓ 16.59%

	FY18	Y/Y Change
Operating Cash Flow	$13.4B	↑ 34.81%
Investing Cash Flow	$-1.0B	↑ 267.15%
Financing Cash Flow	$-14.4B	↑ 161.18%

	FY19	Y/Y Change
Operating Cash Flow	$13.3B	↓ 0.77%
Investing Cash Flow	$596.0M	↓ 159.24%
Financing Cash Flow	$18.7B	↓ 229.95%

	FY20	Y/Y Change
Operating Cash Flow	$17.6B	↑ 32.0%
Investing Cash Flow	$-37.6B	↓ 6401.51%
Financing Cash Flow	$-11.5B	↓ 161.48%

	FY21	Y/Y Change
Operating Cash Flow	$22.8B	↑ 29.5%
Investing Cash Flow	$-2.3B	↓ 93.76%
Financing Cash Flow	$-19.0B	↑ 65.54%

	FY22	Y/Y Change
Operating Cash Flow	$24.9B	↑ 9.51%
Investing Cash Flow	$-623.0M	↓ 73.42%
Financing Cash Flow	$-24.8B	↑ 30.27%

	FY23	Y/Y Change
Operating Cash Flow	$22.8B	↓ 8.44%
Investing Cash Flow	$-2.0B	↑ 222.47%
Financing Cash Flow	$-17.2B	↓ 30.56%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$6.3B	↑ 50.7%
Investing Cash Flow	$-341.0M	↓ 31.66%
Financing Cash Flow	$-3.9B	↓ 36.69%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$7.6B	↑ 19.86%
Investing Cash Flow	$-369.0M	↑ 8.21%
Financing Cash Flow	$-2.7B	↓ 32.12%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$4.8B	↓ 37.25%
Investing Cash Flow	$-800.0M	↑ 116.8%
Financing Cash Flow	$-4.4B	↑ 67.19%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$4.0B	↓ 15.0%
Investing Cash Flow	$-9.6B	↑ 1098.5%
Financing Cash Flow	$10.8B	↓ 343.18%

Abbvie Technicals Summary

Sell

Neutral

Buy

Abbvie is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Abbvie Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Abbvie Inc	-3.83%	-2.64%	2.42%	29.81%	105.36%
Eli Lilly And Company	-8.86%	-15.6%	15.25%	201.86%	421.84%
Johnson & Johnson	1.21%	-5.92%	-8.0%	-9.78%	-0.87%
Merck & Co. Inc.	-1.46%	-22.24%	-18.29%	24.22%	13.89%
Novo Nordisk A/s	-11.3%	-40.21%	-25.32%	64.9%	157.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Abbvie Inc	59.78	59.78	0.41	10.75	0.56	0.08	0.04	3.41
Eli Lilly And Company	78.12	78.12	0.69	12.98	0.65	0.14	0.01	15.83
Johnson & Johnson	24.34	24.34	0.86	9.97	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.49	20.49	0.07	7.69	0.28	0.11	0.03	17.58
Novo Nordisk A/s	26.86	26.86	1.28	23.09	0.89	0.21	0.02	27.07

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Abbvie Inc	Buy	$303.2B	105.36%	59.78	9.22%
Eli Lilly And Company	Buy	$652.7B	421.84%	78.12	20.48%
Johnson & Johnson	Buy	$354.0B	-0.87%	24.34	16.74%
Merck & Co. Inc.	Buy	$247.7B	13.89%	20.49	19.23%
Novo Nordisk A/s	Buy	$352.9B	157.66%	26.86	35.01%

Abbvie Dividend announcements

Abbvie Dividends March, 2025
In the quarter ending March,2025. Abbvie has declared dividend of $1.64
Read More

About Abbvie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Organization	Abbvie
Employees	50000
CEO	Mr. Richard A. Gonzalez
Industry	Health Technology

Management People of Abbvie

Name	Title
Mr. Richard A. Gonzalez	Executive Chairman
Mr. Robert A. Michael CPA	CEO & Director
Mr. Scott T. Reents	Executive VP & CFO
Dr. Azita Saleki-Gerhardt Ph.D.	Executive VP & COO
Mr. Jeffrey Ryan Stewart	Executive VP & Chief Commercial Officer
Dr. Roopal Thakkar M.D.	Executive VP of Research and Development & Chief Scientific Officer
Ms. Elizabeth Shea	Senior Vice President of Investor Relations
Mr. Perry C. Siatis	Executive VP, General Counsel & Secretary
Mr. Sanjay Narayan	Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Timothy J. Richmond	Executive VP & Chief Human Resources Officer

Important FAQs about investing in Abbvie from India :

What is Abbvie share price today?

Abbvie share price today stands at $172.61, Open: $172.16 ; Previous Close: $171.56 ; High: $175.56 ; Low: $171.28 ; 52 Week High: $207.32 ; 52 Week Low: $153.58. The stock opens at $172.16, after a previous close of $171.56. The stock reached a daily high of $175.56 and a low of $171.28, with a 52-week high of $207.32 and a 52-week low of $153.58.

Can Indians buy Abbvie shares?

Yes, Indians can invest in the Abbvie (ABBV) from India.

With INDmoney, you can buy Abbvie at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Abbvie at zero transaction cost.

How can I buy Abbvie shares from India?

It is very easy to buy Abbvie from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Abbvie be purchased?

Yes, you can buy fractional shares of Abbvie with INDmoney app.

What are the documents required to start investing in Abbvie stocks?

To start investing in Abbvie, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.